KRAS and neoplasm: In conclusion, discovery of the tumor-specific and mutant KRAS-reactive TCRs in the presented cases implies that our strategy to identify and select tumor-specific TCRs can be applied to many patients with different tumors, provided that surgical material for analysis is available.